Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 10/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | DRD3 | P35462 | 2/20 | 0.53 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7645609 | 0.86 | PNMT (0.53) | PNMTDRD2DRD3HTR2AHTR2C | |
| SCHEMBL24265339 | 0.81 | PNMT (0.54) | PNMTDRD2DRD3PRMT5HTR2A | |
| SCHEMBL19678855 | 0.79 | PNMT (0.49) | PNMTDRD2DRD3PRMT5HTR2A | |
| SCHEMBL19684575 | 0.78 | PNMT (0.47) | PNMTHTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL23735310 | 0.77 | PNMT (0.46) | PNMTADRA2AADRA2BADRA2CCD44 | |
| SCHEMBL22549231 | 0.76 | PNMT (0.45) | PNMTDRD2DRD3HTR2AHTR2C | |
| SCHEMBL19684576 | 0.75 | PNMT (0.53) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL19684582 | 0.75 | PNMT (0.44) | PNMTHTR2AHTR2CADRA2AADRA2B | |
| SCHEMBL15503204 | 0.75 | PNMT (0.49) | PNMTDRD2HTR2BADRA2AADRA2B | |
| SCHEMBL19684577 | 0.75 | PNMT (0.50) | PNMTPRMT5HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464249-B1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2017213825-A1 | TREATMENT METHODS HAVING REDUCED DRUG-RELATED TOXICITY AND METHODS OF IDENTIFYING THE LIKELIHOOD OF PATIENT HARM FROM PRESCRIBED MEDICATIONS | TABULA RASA HEALTHCARE, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348313-A1 | SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS | DUT, NCL, TYMP | PNMT 2003/4885DRD2 3868/4885DRD3 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.